Clinical Studies on Combined CIK and DCs from Different Tissues to Treat Patients of Moderate and Advanced Stage Lung Cancer

This paper studies individualized treatment of patients of advanced cancer,using Peripheral Blood Mononuclear Cells (PBMCs)of autologous,homologous and unbilical cord blood,and Cytokine Induced Killer(CIK)Cells and Dendritic Cells(DC), cultured with cytokine.The phenotypes of CIK and DC-CIK were analyzed by FACS.Then the patients of moderate and advanced stage lung cancer were administrated by CIK in combination with DC of autologous,homologous and unbilical cord blood.Results show that there are 2 cases of patients of Complete Remission(CR), 7 cases of Partial Remission(PR)in the 21 cases.Life quality has been significantly improved.The levels of CD3~+/CD8~+ were increased significantly(P0.05)as compared with those before treatment.It is concluded that the individualized treatment of CIK in combination with DC from different tissues is effective for treatments against moderate and advanced stage lung cancers,and it serves as a new and efficacious immunity therapeutic tool.